← All trials
NCT05121831
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2022
- Primary completion
- Aug 22, 2022
- Completion date
- Nov 10, 2022
- First posted
- Nov 16, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 56
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Digestome TherapeuticsLead sponsor
- Digestome TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.